Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine + Naltrexone for AUD and PTSD
NCT03852628Phase 2Terminated
- Sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine extended-release injection, naltrexone in alcohol use disorder (AUD), post-traumatic stress disorder (PTSD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance. Started May 2019; status: terminated.
02
Drugs
buprenorphine extended-release injectionnaltrexone
03
Conditions
alcohol use disorder (AUD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03852628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852628.